MeSH tree: E04.936.225.687.500
Acute myeloid leukemia (AML) is a particularly aggressive form of blood cancer that usually progresses rapidly if swift and intensive treatment is not applied. Although the disease can often be contained by chemotherapy (remission), ...
Mar 5, 2026
0
0
Acute myeloid leukemia (AML) is an aggressive form of blood cancer. It affects people of all ages but is most common in those over 65. Around 150 people are diagnosed with the disease each year in Norway. Men are affected ...
Feb 13, 2026
0
36
Cell and gene therapies, or CGT, have come a long way since they were first introduced. In the last few decades, both cell therapy—the transplantation of living cells—and gene therapy—the use of genetic material to ...
Feb 13, 2026
0
0
In modern medicine, antibiotics are among the most powerful tools for preventing and treating life-threatening bacterial infections. Their effectiveness, however, often depends on using the right drug at the right time. Recognizing ...
Feb 5, 2026
0
0
Serenity Cole enjoyed Christmas last month relaxing with her family near her St. Louis home, making crafts and visiting friends. It was a contrast to how Cole, 18, spent part of the 2024 holiday season. She was in the hospital—a ...
Jan 26, 2026
0
4
Compared with white patients, Black patients with an aggressive form of leukemia—called acute myeloid leukemia (AML)—were on average more than five years younger at diagnosis and more than 30% more likely to die of their ...
Dec 17, 2025
0
0
The U.S. Food and Drug Administration has approved Waskyra (etuvetidigene autotemcel) as the first cell-based gene therapy for the treatment of Wiskott-Aldrich syndrome (WAS).
Dec 16, 2025
0
0
A small group of patients with an otherwise incurable form of T‑cell leukemia have seen their cancer driven into remission by an innovative form of immune therapy.
Dec 10, 2025
0
0
A new treatment using genome-edited immune cells, developed by scientists at UCL (University College London) and Great Ormond Street Hospital (GOSH), has shown promising results in helping children and adults fight a rare ...
Dec 8, 2025
0
12
In a new trial, patients newly diagnosed with acute myeloid leukemia (AML) fared significantly better with a combined regimen of azacitidine and venetoclax compared with conventional induction chemotherapy. The azacitidine–venetoclax ...
Dec 8, 2025
0
0
